<
The role and responsibility of our pharmaceutical entity.
Smart Tumor Targeting
Imagine a drug with the advantages of improved pharmacokinetics and drug release, enhanced intracellular penetration, tumor targeting and minimal to no adverse side effects.
Go to Lipoplatin™ mini sitePress Releases
2011 Phase III results ns-NSCLC
Oct, 2011
2010 Phase III Lipoplatin NSCLC
Nov, 2010
Lipoplatin as a radiosensitizer
Nov, 2009
Lipoplatin labeled with fluorescein
Sept, 2009
EMEA ORPHAN DRUG STATUS - Lipoplatin
Sept, 2007